[go: up one dir, main page]

CY1115707T1 - Στερεα σταθεροποιημενα θεραπευτικα συστηματα ταχειας και/ή τροποποιημενης απελευθερωσης για τη χορηγηση απο του στοματος υγρων δραστικων ουσιων, εκδοχων ή τροφιμων - Google Patents

Στερεα σταθεροποιημενα θεραπευτικα συστηματα ταχειας και/ή τροποποιημενης απελευθερωσης για τη χορηγηση απο του στοματος υγρων δραστικων ουσιων, εκδοχων ή τροφιμων

Info

Publication number
CY1115707T1
CY1115707T1 CY20141100882T CY141100882T CY1115707T1 CY 1115707 T1 CY1115707 T1 CY 1115707T1 CY 20141100882 T CY20141100882 T CY 20141100882T CY 141100882 T CY141100882 T CY 141100882T CY 1115707 T1 CY1115707 T1 CY 1115707T1
Authority
CY
Cyprus
Prior art keywords
therapeutic
liberty
administration
modified
systems
Prior art date
Application number
CY20141100882T
Other languages
English (en)
Inventor
Maria Gabriella Massironi
Original Assignee
Farmatron Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Farmatron Ltd. filed Critical Farmatron Ltd.
Publication of CY1115707T1 publication Critical patent/CY1115707T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Μέθοδος για τη σύνθεση υγρών δραστικών συστατικών σε στερεές φαρμακευτικές, διαιτητικές ή διατροφικές συνθέσεις. Η μέθοδος περιλαμβάνει προσθήκη των δραστικών συστατικών προς μία τετηγμένη μάζα, η οποία αποτελείται από αμφίφιλες ενώσεις, με σημείο τήξης ή μαλάκυνσης το οποίο κυμαίνεται από 30°C έως 60°C και/ή από λιπόφιλες ενώσεις με σημείο τήξης το οποίο κυμαίνεται από 40°C έως 90°C και ενδεχομένως προσθήκη σκόνης δραστικών φαρμακευτικών συστατικών ή εκδόχων και ακολούθως σύνθεση των τελικών συνθέσεων.
CY20141100882T 2001-11-09 2014-10-29 Στερεα σταθεροποιημενα θεραπευτικα συστηματα ταχειας και/ή τροποποιημενης απελευθερωσης για τη χορηγηση απο του στοματος υγρων δραστικων ουσιων, εκδοχων ή τροφιμων CY1115707T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT2001MI002366A ITMI20012366A1 (it) 2001-11-09 2001-11-09 Sistemi terapeutici stabilizzati a rilascio immediato e/o modificato per la somministrazione orale di principi attivi e/o eccipienti e/o ali
EP02787578.0A EP1441705B1 (en) 2001-11-09 2002-11-06 Solid, stabilized, prompt- and/or modified-release therapeutical systems for the oral administration of liquid active principles, excipients or foodstuffs

Publications (1)

Publication Number Publication Date
CY1115707T1 true CY1115707T1 (el) 2017-01-25

Family

ID=11448588

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20141100882T CY1115707T1 (el) 2001-11-09 2014-10-29 Στερεα σταθεροποιημενα θεραπευτικα συστηματα ταχειας και/ή τροποποιημενης απελευθερωσης για τη χορηγηση απο του στοματος υγρων δραστικων ουσιων, εκδοχων ή τροφιμων

Country Status (11)

Country Link
US (1) US20050037068A1 (el)
EP (1) EP1441705B1 (el)
JP (1) JP2005508982A (el)
AU (1) AU2002351850B2 (el)
CA (1) CA2466529C (el)
CY (1) CY1115707T1 (el)
DK (1) DK1441705T3 (el)
ES (1) ES2515790T3 (el)
IT (1) ITMI20012366A1 (el)
PT (1) PT1441705E (el)
WO (1) WO2003039521A1 (el)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2957281A1 (en) 2001-09-21 2015-12-23 Egalet Ltd. Polymer release system
US20040253310A1 (en) 2001-09-21 2004-12-16 Gina Fischer Morphine polymer release system
IS1935B (is) * 2002-03-19 2004-06-16 Actavis Group Hf. Fósínópríl lyfjasamsetning
EP1592760A4 (en) * 2003-01-31 2009-08-12 Smithkline Beecham Corp AS FIXED DISPERSIONS, COMPOSITIONS
EP1750717B1 (en) * 2004-02-11 2017-07-19 Rubicon Research Private Limited Controlled release pharmaceutical compositions with improved bioavailability
US20060134212A1 (en) * 2004-09-02 2006-06-22 Forest Laboratories, Inc. Lercanidipine immediate release compositions
US20060165788A1 (en) * 2004-09-09 2006-07-27 Wattanaporn Abramowitz Lercanidipine pH dependent pulsatile release compositions
US20060165789A1 (en) * 2004-09-09 2006-07-27 Forest Laboratories, Inc. Lercanidipine modified release compositions
JP5161075B2 (ja) * 2005-06-03 2013-03-13 エガレット エイ／エス 分散媒体の第１フラクションとマトリックスの第２フラクションを有し、第２フラクションが胃腸の液体に少なくとも部分的に最初に曝される固形の医薬組成物
WO2007055327A1 (ja) * 2005-11-11 2007-05-18 Mochida Pharmaceutical Co., Ltd. ゼリー組成物
GB0524961D0 (en) * 2005-12-07 2006-01-18 Pharmakodex Ltd Transdermal administration of active agents for systemic effect
PL3095447T3 (pl) 2006-02-03 2022-02-14 Opko Renal, Llc Leczenie niedoboru lub deficytu witaminy d 25-hydroksywitaminą d2 i 25- hydroksywitaminą d3
ES2670029T3 (es) 2006-06-21 2018-05-29 Opko Ireland Global Holdings, Ltd. Terapia usando agente de repleción de la vitamina D y agente de reemplazo de la hormona de la vitamina D
WO2008021666A2 (en) * 2006-08-18 2008-02-21 Morton Grove Pharmaceuticals, Inc. Stable liquid levetiracetam compositions and methods
EP1952806A1 (en) 2007-02-01 2008-08-06 Helm AG Process for the preparation of adsorbates of candesartan
JP2010525080A (ja) 2007-04-25 2010-07-22 プロヴェンティヴ セラピュティックス リミテッド ライアビリティ カンパニー 慢性腎臓病における続発性副甲状腺機能亢進症の安全かつ効果的な治療および予防方法
KR101959952B1 (ko) * 2007-04-25 2019-03-19 사이토크로마 인코포레이티드 비타민 ｄ 화합물과 밀랍성 담체를 포함하는 경구 조절성 방출 조성물
KR101495578B1 (ko) 2007-04-25 2015-02-25 사이토크로마 인코포레이티드 비타민 ｄ 부족 및 결핍의 치료 방법
CA2684778C (en) 2007-04-25 2017-09-05 Cytochroma Inc. Methods and compounds for vitamin d therapy
AU2008258596B2 (en) 2007-06-04 2013-02-14 Egalet Ltd Controlled release pharmaceutical compositions for prolonged effect
EP2220208A4 (en) * 2007-11-23 2010-12-29 Rappaport Family Inst For Res USE OF HAPTOGLOBIN ENTYPIZATION FOR THE DIAGNOSIS AND TREATMENT OF CARDIOVASCULAR DISEASES
ES2954932T3 (es) 2008-04-02 2023-11-27 Eirgen Pharma Ltd Métodos, composiciones, usos y kits útiles para la deficiencia de vitamina D y trastornos relacionados
PT2165702E (pt) 2008-09-17 2012-02-07 Helm Ag Composições estáveis e rapidamente dissolvidas de candesartan cilexetil preparadas com granulação húmida
NZ594207A (en) 2009-02-06 2013-03-28 Egalet Ltd Immediate release composition resistant to abuse by intake of alcohol
EP2445487A2 (en) 2009-06-24 2012-05-02 Egalet Ltd. Controlled release formulations
CN102612375B (zh) 2009-09-15 2016-01-27 Qlt股份有限公司 含有在脂质媒介物中的9-顺式-视黄酯的药物制剂
EP2554185A4 (en) * 2010-03-29 2014-09-24 Kaneka Corp COATING FAT COMPOSITION AND PARTICLE COMPOSITION THEREWITH
PT2552484T (pt) 2010-03-29 2020-04-03 Opko Ireland Global Holdings Ltd Métodos e composições para redução dos níveis de parafróides
SG10201507819VA (en) 2010-04-19 2015-10-29 Quadra Logic Tech Inc Therapeutic Regimen And Methods For Treating Or Ameliorating Visual Disorders Associated With An Endogenous Retinoid Deficiency
CN102552923A (zh) * 2012-01-31 2012-07-11 辽宁思百得医药科技有限公司 包含左卡尼汀和辅酶q10的药物组合物及其制备方法
JP6576636B2 (ja) 2012-03-01 2019-09-18 ノベリオン セラピューティクス インコーポレイテッド 内因性レチノイド欠乏に関連する視覚障害における視覚機能を改善するための治療的計画および方法
KR20150059167A (ko) 2012-07-06 2015-05-29 에갈렛 리미티드 제어된 방출을 위한 남용 제지 약학적 조성물
KR101847947B1 (ko) 2013-03-15 2018-05-28 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 안정화되고 변형된 비타민 ｄ 방출 제형
US9375033B2 (en) 2014-02-14 2016-06-28 R.J. Reynolds Tobacco Company Tobacco-containing gel composition
US10220047B2 (en) 2014-08-07 2019-03-05 Opko Ireland Global Holdings, Ltd. Adjunctive therapy with 25-hydroxyvitamin D and articles therefor
KR101710441B1 (ko) * 2015-12-28 2017-02-28 신풍제약주식회사 안정성 및 용출성이 향상된 정제
US9687475B1 (en) 2016-03-24 2017-06-27 Ezra Pharma Llc Extended release pharmaceutical formulations with controlled impurity levels
US9675585B1 (en) 2016-03-24 2017-06-13 Ezra Pharma Extended release pharmaceutical formulations
EP3436026A1 (en) 2016-03-28 2019-02-06 OPKO Ireland Global Holdings, Ltd. Methods of vitamin d treatment
GB201716419D0 (en) 2017-10-06 2017-11-22 Univ Central Lancashire Solid composition

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6112632A (ja) * 1984-06-27 1986-01-21 Eisai Co Ltd 脂溶性薬剤含有組成物
HU202753B (en) * 1986-06-21 1991-04-29 Sandoz Ag Process for producing retard pharmaceutical compositions containing cetotiphene
LU87416A1 (fr) * 1988-12-29 1990-07-10 Cird Microgranules charges en une substance active,constitues essentiellement d'un triglyceride d'acides gras satures et leur utilisation par voie topique dans le domaine therapeutique
TW209174B (el) * 1991-04-19 1993-07-11 Takeda Pharm Industry Co Ltd
US5800834A (en) * 1996-06-10 1998-09-01 Spireas; Spiridon Liquisolid systems and methods of preparing same
WO1999006035A2 (en) * 1997-07-31 1999-02-11 Kos Pharmaceuticals, Inc. COMBINATIONS OF HMG-CoA REDUCTASE INHIBITORS AND NICOTINIC ACID COMPOUNDS AND METHODS FOR TREATING HYPERLIPIDEMIA ONCE A DAY AT NIGHT
JPH11152220A (ja) * 1997-11-19 1999-06-08 Daiichi Yakuhin Kogyo Kk 脂溶性薬物を含有した丸剤の製造方法
FR2779651B1 (fr) * 1998-06-16 2001-04-20 Gattefosse Ets Sa Procede pour la fabrication de comprimes a liberation prolongee de principe(s) actif(s) presentant une cinetique de dissolution d'ordre zero
FR2785198B1 (fr) * 1998-10-30 2002-02-22 Rhodia Chimie Sa Granules redispersables dans l'eau comprenant une matiere active sous forme liquide
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
ES2208349T3 (es) * 1999-06-14 2004-06-16 Cosmo S.P.A. Composiciones farmaceuticas administrables por via oral de liberacion controlada y enmascaradoras del sabor.
EP1188440A4 (en) * 1999-06-18 2004-04-14 Yamanouchi Pharma Co Ltd MEDICINAL COMPOSITION FOR ORAL ADMINISTRATION
DE19954923A1 (de) * 1999-11-16 2001-05-17 Bitec Gmbh Verfahren zur Herstellung von gereinigten Pulvern sowie danach erhältliche Pulver
US6793934B1 (en) * 1999-12-08 2004-09-21 Shire Laboratories, Inc. Solid oral dosage form
EP1116515A3 (en) * 2000-01-11 2002-08-21 Givaudan SA Encapsulated liquid

Also Published As

Publication number Publication date
CA2466529C (en) 2012-07-10
ES2515790T3 (es) 2014-10-30
ITMI20012366A1 (it) 2003-05-09
AU2002351850B2 (en) 2008-01-24
EP1441705A1 (en) 2004-08-04
PT1441705E (pt) 2014-10-20
EP1441705B1 (en) 2014-09-03
WO2003039521A1 (en) 2003-05-15
DK1441705T3 (da) 2014-11-03
US20050037068A1 (en) 2005-02-17
CA2466529A1 (en) 2003-05-15
JP2005508982A (ja) 2005-04-07

Similar Documents

Publication Publication Date Title
CY1115707T1 (el) Στερεα σταθεροποιημενα θεραπευτικα συστηματα ταχειας και/ή τροποποιημενης απελευθερωσης για τη χορηγηση απο του στοματος υγρων δραστικων ουσιων, εκδοχων ή τροφιμων
BG66093B1 (bg) Състави с контролирано освобождаване, съдържащи нимесулид
NO20022058L (no) Farmasöytiske sammensetninger
EE200300033A (et) Tsüklopentanoindoolid, nende kasutamine ravimi valmistamiseks ning neid sisaldav farmatseutiline kompositsioon
DE60334773D1 (de) Formulierungen zur oralen verabreichung von wirkstoffen
PL410219A1 (pl) Kompozycja zawierająca koniugat leku obejmujący pochodne kalicheamycyny i przeciwciało, oraz kompozycja farmaceutyczna ją zawierająca
ATE293995T1 (de) Pharmazeutische zusammensetzungen, die wirkstoffabsorptionsfördernde verbindungen enthalten
GEP20063741B (en) Nonaryl-Heterocyclic NMDA/NR2B Antagonists
ATE270544T1 (de) Halbfeste arzneizubereitung enthaltend isotretinoin
CY1105559T1 (el) Φαρμακευτικες συνθεσεις του tegaserod
ATE332138T1 (de) Flibanserin zur behandlung extrapyramidaler bewegungsstörungen
AR033711A1 (es) Composiciones farmaceuticas
CY1112376T1 (el) Παραγωγα 2,3,4,9-τετραϋδρο-1η-καρβαζολης ως ανταγωνιστες του υποδοχεα crth2
CY1110906T1 (el) Φαρμακευτικη συνθεση για ρινικη χορηγηση φεντανυλης
SG147450A1 (en) Sustained release pharmaceutical compositions comprising aplindore and derivatives thereof
IS7006A (is) Tvívetnis 3-piperidínóprópíófenon og lyf sem innihalda téð efnasambönd
EP1365749A4 (en) PROCESS FOR PREPARING PHARMACEUTICAL COMPOSITIONS FOR USE WITH WEICHGELATINE FORMULATIONS
DE602005025755D1 (de) Irbesartan enthaltende pharmazeutische zusammensetzung
DE60336225D1 (de) Neue pharmazeutische zusammenstezungen, flibanserin polymorph a enthaltend
WO2002024203A3 (en) Controlled release formulations for oral administration
BRPI0412364A (pt) composição farmacêutica sólida, compreendendo amisulpride
ATE346592T1 (de) Pharmazeutische zubereitungen mit einem cortisol synthese inhibitor
ATE460934T1 (de) Pharmazeutische zubereitungen von ciprofloxacin
MA26788A1 (fr) COMPOSITIONS PHARMACEUTIQUES DESTINÉES à L'ADMINISTRATION PAR VOIE ORALE DE PHLOROGLUCINOL ET LEUR PRÉPARATION
DZ3103A1 (fr) Nouvelles pyrazolo Ä4,3-EÜdiazépines substituées, compositions pharmaceutiques les contenant, utili sation à titre de médicament et procédés pour leurs préparation.